(Q37873581)

24 August 2017

0 references

1 reference

title

Melatonin receptor agonists: new options for insomnia and depression treatment (English)

1 reference

24 August 2017

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

Annalida Bedini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

Silvia Rivara

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

Marco Mor

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

1

Gilberto Spadoni

1 reference

24 August 2017

2

Annalida Bedini

1 reference

24 August 2017

3

Silvia Rivara

1 reference

24 August 2017

4

Marco Mor

1 reference

21554566

24 August 2017

publication date

1 December 2011

1 reference

21554566

CNS Neuroscience & Therapeutics

24 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

page(s)

733-741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

Persistence of circadian rhythmicity in a mammalian hypothalamic "island" containing the suprachiasmatic nucleus

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Extrapineal melatonin: location and role within diffuse neuroendocrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Comparative Physiology: Pineal Gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Effect of exogenous melatonin on the ovary, the embryo and the establishment of pregnancy in sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin: Characteristics, Concerns, and Prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

The immunotherapeutic potential of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin: a hormone that modulates pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Antioxidative Protection by Melatonin: Multiplicity of Mechanisms from Radical Detoxification to Radical Avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Neuroprotection by radical avoidance: search for suitable agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors: localization, molecular pharmacology and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Functional MT1 and MT2 melatonin receptors in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors are for the birds: Molecular analysis of two receptor subtypes differentially expressed in chick brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Identification of the melatonin-binding site MT3 as the quinone reductase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Are nuclear receptors involved in pituitary responsiveness to melatonin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Cloning of a melatonin-related receptor from human pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors in humans: biological role and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptors and ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Recent advances in melatonin receptor ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

2-Bromomelatonin: synthesis and characterization of a potent melatonin agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

N-acyl-3-amino-5-methoxychromans: a new series of non-indolic melatonin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Heterocyclic aminopyrrolidine derivatives as melatoninergic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin as a hypnotic: pro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin as a hypnotic: con.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin Improves Sleep Quality of Patients With Chronic Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Subtyping major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Agomelatine in the treatment of seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Indanyl piperazines as melatonergic MT2 selective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

4-Substituted anilides as selective melatonin MT2 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis and biological activity of new melatonin dimeric derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

(R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

The Efficacy and Safety of the Melatonin Agonist beta-Methyl-6-Chloromelatonin in Primary Insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00197.X

21 January 2018

1 reference

12 December 2020

Bioavailability of melatonin in humans after day-time administration of D(7) melatonin

1 reference

12 December 2020

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

1 reference

12 December 2020

Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews.

1 reference

12 December 2020

The sleep-promoting action of ramelteon (TAK-375) in freely moving cats

1 reference

12 December 2020

The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial

1 reference

12 December 2020

Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment

1 reference

12 December 2020

Towards the Development of Mixed MT1-Agonist/MT2-Antagonist Melatonin Receptor Ligands

1 reference

12 December 2020

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

1 reference

12 December 2020

Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia

1 reference

12 December 2020

Iodinated melatonin: preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy

1 reference

12 December 2020

Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily

1 reference

12 December 2020

2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity

1 reference

12 December 2020

2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents

1 reference

12 December 2020

Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides

1 reference

12 December 2020

Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors

1 reference

12 December 2020

GR196429: a nonindolic agonist at high-affinity melatonin receptors.

1 reference

12 December 2020

10.1111/J.1755-5949.2010.00197.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493855&resulttype=core&format=json

14 May 2020

21554566

1 reference